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Lucy Ly3, Kaye J Williams4, Rachel E Airley5, Adrian L Harris6, John Latigo7, Meg Perumal7, Eric O Aboagye7,
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Abstract
Background: HIF-1 deficiency has marked effects on tumour glycolysis and growth. We therefore investigated the
consequences of HIF-1 deficiency in mice, using the well established Hepa-1 wild-type (WT) and HIF-1b-deficient
(c4) model. These mechanisms could be clinically relevant, since HIF-1 is now a therapeutic target.
Methods: Hepa-1 WT and c4 tumours grown in vivo were analysed by 18FDG-PET and 19FDG Magnetic Resonance
Spectroscopy for glucose uptake; by HPLC for adenine nucleotides; by immunohistochemistry for GLUTs; by
immunoblotting and by DIGE followed by tandem mass spectrometry for protein expression; and by classical
enzymatic methods for enzyme activity.
Results: HIF-1b deficient Hepa-1 c4 tumours grew significantly more slowly than WT tumours, and (as expected)
showed significantly lower expression of many glycolytic enzymes. However, HIF-1b deficiency caused no
significant change in the rate of glucose uptake in c4 tumours compared to WT when assessed in vivo by
measuring fluoro-deoxyglucose (FDG) uptake. Immunohistochemistry demonstrated less GLUT-1 in c4 tumours,
whereas GLUT-2 (liver type) was similar to WT. Factors that might upregulate glucose uptake independently of HIF-
1 (phospho-Akt, c-Myc) were shown to have either lower or similar expression in c4 compared to WT tumours.
However the AMP/ATP ratio was 4.5 fold higher (p < 0.01) in c4 tumours, and phosphofructokinase-1 (PFK-1)
activity, measured at prevailing cellular ATP and AMP concentrations, was up to two-fold higher in homogenates
of the deficient c4 cells and tumours compared to WT (p < 0.001), suggesting that allosteric PFK activation could
explain their normal level of glycolysis. Phospho AMP-Kinase was also higher in the c4 tumours.
Conclusions: Despite their defective HIF-1 and consequent down-regulation of glycolytic enzyme expression,
Hepa-1 c4 tumours maintain glucose uptake and glycolysis because the resulting low [ATP] high [AMP]
allosterically activate PFK-1. This mechanism of resistance would keep glycolysis functioning and also result in
activation of AMP-Kinase and growth inhibition; it may have major implications for the therapeutic activity of HIF
inhibitors in vivo. Interestingly, this control mechanism does not involve transcriptional control or proteomics, but
rather the classical activation and inhibition mechanisms of glycolytic enzymes.
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Background
The HIF-1 pathway, which enables cells to respond to
hypoxia, plays important roles in tumour growth, angio-
genesis, glucose uptake, glycolytic metabolism, pH regu-
lation (through carbonic anhydrase), apoptosis, tissue
matrix and iron metabolism [for reviews see [1,2]].
However, in many cases after a period of slow growth,
HIF-1 deficient tumours have shown the ability to accel-
erate their growth [3,4] but the mechanisms for escape
from inhibition of HIF-1 function are poorly under-
stood. We therefore investigated the mechanisms by
which cells can overcome HIF-1 deficiency to enhance
tumour growth in vivo. These mechanisms are also
likely to be relevant to the way cells adapt to inhibition
of HIF signalling by novel anticancer drugs, as HIF-1 is
now a major therapeutic target [5-7]. Since a major
effect of HIF-1 activation is upregulation of glucose
uptake and glycolysis one would expect to be able to
use the uptake of fluorodeoxyglucose, detected by
18FDG-PET, as a surrogate biomarker for monitoring
the anti-proliferative action of anti-HIF-1 drugs [7].
Such a strategy assumes that the effect of HIF-1 on gly-
colysis can be used to indicate its effect on proliferation;
it is important, therefore, to examine whether this rela-
tionship can be relied upon.
In this study we have compared the growth and meta-
bolism of Hepa-1 wild-type (WT) and HIF-1 b-deficient
(c4) Hepa-1 cells grown as tumours in vivo. This well-
established model has been used in several previous stu-
dies [3,4,8-10]. In one of these studies [10] we showed
that c4 cells cannot form a functional HIF-1 complex as
no HIF- 1 a or b subunits were detectable in their cell
nuclei; nor was there any activation of HIF-1-dependent
gene transcription via HRE elements [4,10]. Surprisingly,
despite the absence of a functioning HIF-1 pathway in
the c4 cells they were able to activate glycolysis to lac-
tate, when cultured under hypoxia, to the same extent
as WT cells. In an earlier study [9] we had also found
very low (20% of the level in WT tumours) ATP in c4
tumours, and attributed that to an effect of HIF-1 defi-
ciency on the anabolic pathway for adenine nucleotide
synthesis. Results obtained in the present study led us to
a different conclusion.
We began the present investigation by using two non-
invasive methods to measure the glucose uptake in HIF-
1 b-deficient c4 and WT tumours in vivo, and found
that the HIF-1b deficient c4 tumours took up as much
glucose as the HIF-1 competent WT tumours. This was
unexpected as HIF-1 upregulates transcription of most
glycolytic enzymes and is generally regarded as the main
effector of the Warburg effect - i.e. the enhanced glyco-
lytic flux observed in cancers. No alternative mechan-
isms involving control of gene transcription (e.g. by Akt
or C-Myc) were found in the c4 tumours, and
proteomic studies demonstrated that most of their gly-
colytic enzymes were in fact under-expressed compared
to the WT tumours (as would be expected). We even-
tually found that the anomalously high rate of glucose
uptake by c4 tumours could only be understood in
terms of the classical allosteric activation and inhibition
mechanisms by which small-molecule metabolites con-
trol the enzymes of the glycolytic pathway. This finding
is of some general interest: in recent years the intensive
development of genomic, transcriptomic and proteomic
methods has tended to focus most cancer biology
research onto the expression and post-translational
modification of proteins in signalling pathways. The
result of the present study suggests that the abnormal
metabolism of cancers also involves the classical
mechanisms of enzymatic control.
Materials And Methods
Cell culture and tumour implantation in nude mice
Hepa-1 c4 and WT cells were routinely cultured in
MEM alpha medium (Gibco BRL) supplemented with
10% foetal calf serum in a humidified atmosphere con-
taining 95% air and 5% CO2. The c4 cells were originally
derived from the murine hepatoma line Hepa1c2c7
(Hepa-1 WT) [11]. MF1 athymic nude mice were
injected subcutaneously in the flanks with 106 c4 or WT
cells in 0.1 ml PBS. The tumours were examined at
~300-500 mm3 except where stated otherwise. Tumour
volume was calculated by measuring the length, width,
and depth using callipers and the formula l*w*d*(π/6)
every third day of the growth curve. All experiments
were performed in accordance with the UK Home
Office Animals Scientific Procedures Act 1986 and
national UK Coordinating Committee on Cancer
Research’s (UKCCCR) guidelines.
Adenine Nucleotides
Measurements of adenine nucleotides were made on
neutralised extracts obtained from freeze clamped mate-
rial, of both c4 and WT tumours by HPLC [12].
Enzyme activity measurements
The activities of pyruvate kinase (EC 2.7.1.4), lactate
dehydrogenase (EC 1.1.2.5) and phosphofructokinase
(EC2.7.1.11) were made using standard spectrophoto-
metric methods according to Board et al., [13] on
homogenates of WT and c4 cultured cells and tumours.
PET measurement of 18FDG in vivo
18FDG was injected via the tail vein into anaesthetized
(isofluorane/N2O/O2) mice placed prone in a thermosta-
tically-controlled jig within the bore of the scanner.
Emission scans were acquired for 1 hour on a quad-
HIDAC scanner (Oxford Positron Systems, Oxon) in
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list-mode format. The acquired list-mode data were
reconstructed to give 0.5 × 0.5 × 0.5 mm pixel size and
19 time frames (15sx4; 60sx4; 300sx11). 18fluoro-deoxy-
D-glucose-6-phosphate (FDG-P) retention was expressed
as standardised uptake (SUV) (for further details see
Additional File).
19F-MRS measurement of FDG in vivo
Animals were anaesthetised with a single i.p. injection of
a Hypnovel-Hypnorm-water mixture (1:1:2). Animals
were placed in the bore of a Varian 4.7T spectrometer
at 37°C and tumours were positioned in the centre of a
12 mm dual-tuned 1H/19F surface coil. 200 mg/kg FDG
was injected i.p. Non-localised 19F spectra were acquired
immediately in 10 minute blocks (1500 transients with
TR of 0.4s, spectral width of 20 kHz, 45° pulse at coil
centre) for up to 180 minutes [14]. In vivo quantitation
was achieved by making a comparison with the water
signal, assuming the concentration of tumour water pro-
tons to be 94.4 M.
Proteomic analysis
Tumour tissue from c4 and WT tumours was frozen
immediately in liquid nitrogen to avoid protein degrada-
tion before the proteomic analysis. Protein extracts were
prepared from homogenized tumours using standard
lysis buffer (9 M urea, 1% DTT, 4% CHAPS, 0.8% Phar-
malytes 3-10, protease and phosphatase inhibitors
(Complete Mini, Roche)). After centrifugation at 13,000
g for 10 minutes, the supernatant containing soluble
proteins was harvested and the protein concentration
was determined using a modification of the method
described by Bradford [15]. Solubilised samples were
divided into aliquots and stored at -80°C. For further
details of the Difference in-Gel Electrophoresis (DIGE)
and tandem mass spectrometry methods used (see Addi-
tional File).
Immunoblotting
Protein extracts were made from frozen sections of
tumours using T-PER tissue protein extraction kit, sup-
plemented with protease inhibitors (Roche) following
the manufacturer’s instructions (Pierce). Protein extracts
were separated on 10% SDS-PAGE and transferred to
polyvinylidene difluoride membrane. Primary antibodies
used were goat pyruvate kinase (1:500) (Biogenesis),
goat lactate dehydrogenase (1:500) (Abcam), rabbit c-
Myc (1:1000) (Cell Signalling), rabbit phospho c-Myc
(Thr58/Ser62) (1:1000) (Cell Signalling), mouse phospho
Akt (Ser473) (1:500) (Cell Signalling), rabbit Akt
(1:1000) (Cell Signalling), rabbit Phospho-AMPKa
(Thr172) (1:1500) (Cell Signalling) and mouse anti-ß-
actin (1:1000) monoclonal antibody (Sigma). Immunor-
eactivity was visualized with horseradish peroxidase-
linked goat anti-mouse or anti-rabbit serum (DAKO) at
1:1000 and detected with enhanced chemiluminescence
(Amersham). Antibodies for PDK1 and PDK2 were sup-
plied and assays performed by Professor Mary Sugden
using E1a as a standard.
Immunohistochemistry for GLUT-1 and 2
Immunostaining for GLUT-1 and GLUT-2 expression
was performed on serial sections as described in [16,17].
For GLUT-2 staining an additional antigen retrieval step
was included prior to the endogenous peroxidase block-
ing step, consisting of boiling in a microwave for 25
minutes in 10 mM citric acid in TBS pH 6. Primary
antibodies used included affinity purified anti-rabbit
GLUT-1 and GLUT-2 (obtained from Alpha Diagnostic
International, Texas, USA) at a working dilution of 1/
100 (protein concentration 10 μg/ml); for negative con-
trols a 10 μg/ml dilution of rabbit IgG (Menarini Diag-
ostics (Menapath) X-Cell Plus HRP detection kit) was
used.
Statistical Analysis
All data, except the proteomic data (for details see text
and Additional File) are presented as Mean + SEM,
using a two tailed unpaired t test with P < 0.05 for
significance.
Results
The effect of HIF-1b deficiency on tumour growth rate
Similar to previous studies we found the growth rate of
the c4 tumours was slower than that of WT tumours
over the first 24 days (Figure 1A). There were significant
differences in tumour sizes at days 17, 21 and 24 (p <
0.05). Plotted as an exponential growth curve it can be
seen that the HIF-1 deficient c4 tumours demonstrate a
significant growth delay in comparison to the WT
tumours. However between 24-28 days the growth rate
of the c4 tumours and the WT tumours were not signif-
icantly different (P > 0.1).
The effect of HIF-1b deficiency on glucose uptake
a) 18FDG-PET
Glucose uptake, when quantified by 18FDG -PET over a
time course of 60 minutes, was very similar in the c4
and WT tumours (Figure 1B). Tracer retention
expressed as the standardized uptake at 60 minutes was
not significantly different in c4 (0.25 ± 0.05) and in WT
(0.24 ± 0.02) tumours (P > 0.1).
b) 19F-MRS
We also performed glucose uptake studies by 19F-MRS,
using a method that we had previously developed [14]
in which the level of a peak due to FDG+FDG-6P is
monitored (Figure 1C). The rate of appearance of the
FDG+FDG-6P peak in both c4 and WT tumours was
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similar, with a Cmax of ca. 2 μmoles/g tumour after
about 45 mins. Thereafter, the broad FDG+FDG-6P
resonance decreased slowly, possibly due to formation
of fluorodeoxymannose compounds [14]. Overall, there
was no significant difference in the rate of uptake of the
glucose analogue in the WT and c4 tumours, confirm-
ing the 18FDG-PET results.
Effects of HIF-1b deficiency on glucose transporters
Previous studies had shown that GLUT 1 and 3 were
decreased in the c4 cells [3,4]. However since the rates of
glucose uptake in deficient and WT tumours were similar
(Figure 1B,C) we assessed GLUT-1 by immununohisto-
chemistry. This demonstrated less staining around areas
of necrosis in the c4 compared to WT tumours (Figure
2A, B, C, and 2D) as previously observed [3,4], confirm-
ing that there were fewer glucose transporters in the c4
than in the WT tumours. However, since Hepa-1 cells
are liver-derived, we also stained for GLUT-2, the liver-
type glucose transporter (Figure 2E and 2F, and negative
controls G and H, which are included to help visualise
the brown GLUT-2 staining), and although the staining
was weak, it was equally positive for both c4 and WT.
Effects of HIF-1b deficiency on other relevant oncogenic
factors
It has been shown that some other oncogenic factors
can upregulate tumour glucose metabolism instead of
HIF-1 [18,19]. Akt has been shown to upregulate glu-
cose uptake and glycolysis, and to promote tumour
growth and glycolysis independently of HIF-1. However,
western blotting showed less expression of phospho-Akt
and no change in total Akt in c4 tumours (Figure 3A).
In addition c-Myc, which has been shown to be a poten-
tial regulator of glycolysis in tumours [20], was found to
have similar levels of expression in both c4 and WT
tumours (Figure 3B). We also measured phospho c-Myc,
the activated species of c-Myc, but this was present at
lower levels in the c4 than the WT tumours. Since
neither the glucose transporters nor oncogenic factors
that might affect glucose metabolism independently of
HIF-1 were upregulated, we next looked at levels of gly-
colytic enzyme proteins.
Effects of HIF-1b deficiency on proteins concerned with
glycolysis
DIGE was used to see whether glycolytic enzyme
expression was downregulated in the c4 tumours, as
would be expected in the absence of a functioning HIF
pathway. 104 spots that showed statistically significant
differences between c4 and WT tumours (see Additional
File 1) were identified by tandem mass spectrometry
and are listed in the Additional File 1, expressed as a
ratio of c4 over WT expression (c4/WT).
As expected, many spots containing glycolytic
enzymes were decreased in the c4 compared to WT
tumours. Table 1 shows significant reductions, by fac-
tors ranging from 1.25 to 2.05, in the differential expres-
sion of the following glycolytic and related enzymes;
triose-phosphate isomerase, glyceraldehyde-3-phosphate
dehydrogenase, phosphoglycerate kinase, phosphoglyce-
rate mutase, fructose bisphosphate aldolase A, enolase,
C
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Figure 1 Growth and FDG uptake characteristics of Hepa-1 c4
and WT tumours. A. Comparison of growth rate from Hepa-1 c4
and WT tumours. The Hepa-1 c4 (●) tumours had a slower growth
rate compared with the WT (□) tumours and growth rates were
significantly different at days 17, 21 and 24 (p < 0.05) (n = 10) but
not at 28 days (p > 0.1). B. The uptake of FDG in Hepa-1 c4 (●) and
WT (□) tumours measured by 18FDG -PET. Data were expressed as
standardised uptake (SUV) (n = 4-6). For details see Methods. C. The
uptake of 19FDG measured by 19F MRS in Hepa-1 c4 (●) and WT (□)
tumours.
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pyruvate kinase (PK and PKM2), D-3-phosphoglycerate
dehydrogenase and L-lactate dehydrogenase A (LDH).
There was also reduced expression in c4 tumours of a
number of other known targets of HIF-1, such as heat
shock proteins and proteins concerned with growth and
apoptosis (see Additional File 1).
As well as differential protein expression by DIGE we
also assessed the expression of several important
enzymes by western blotting. Consistent with the 2-D
gel results, expression of PK and LDH was decreased in
the c4 tumours (Figure 3C). The possibility of increased
pyruvate dehydrogenase kinase (PDK) expression in c4
A B
C  D
E F
G H
Hepa-1 WTHepa-1 c4
-ve GLUT-1
GLUT-2
-ve GLUT-2
GLUT-1
Figure 2 Immunohistochemistry staining for GLUT 1 and 2 in Hepa-1 c4 and WT tumours. Panels show GLUT-1 staining for c4 (A) and WT
(B), negative staining for GLUT-1 in c4 (C) and WT (D), GLUT-2 staining for c4 (E) and WT (F), negative staining for GLUT-2 in c4 (G) and WT (H).
The arrows indicate significant areas of staining.
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Phospho Akt (1:1000)
Akt (1:1000)
actin (1:1000)
cMyc(1:1000)
Phospho cMyc (1:1000)
actin (1:1000)
LDH (1:500)
PK (1:500)
actin (1:1000)
PDK-1
PDK-2
E1α
Phospho AMPK (1:1500)
actin (1:1000)
-----Hepa-1 c4---- -----Hepa-1 WT---
A
B
C
D
E
Figure 3 Protein expression in Hepa-1 c4 and Hepa-1 WT tumours. A. Protein extracts from Hepa-1 c4 and WT tumours analysed by
Western blotting for Akt and its phosphorylated form. For details see Methods.B. Protein extracts from Hepa-1 c4 and WT tumours analysed by
Western blotting for c-Myc and its phosphorylated form. C. Protein extracts from Hepa-1 c4 and WT tumours analysed by Western blotting for
LDH and PK. For details see Methods.D. Protein extracts from Hepa-1 c4 and WT tumours analysed by Western blotting for PDK1 and PDK2.E.
Protein extracts from Hepa-1 c4 and WT tumours analysed by Western blotting for phospho-AMPK.
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tumours was also investigated. PDK is a HIF-1 regulated
enzyme, involved in determining the fate of glucose by
inhibiting the PDH enzyme complex [21,22] and thus
the entry of pyruvate into the TCA cycle. Upregulated
expression of PDK might have accounted for the high
glycolytic rate of c4 tumours. However, Western blot
analyses for two PDK isoenzymes, PDK-1 and PDK-2,
showed less expression in c4 compared with WT
tumours (see Figure 3D).
Effects of HIF-1b deficiency on glycolytic enzyme activity
The western blotting, DIGE and immunohistochemistry
studies described so far have shown that most of the
glucose transporters and glycolytic enzymes were less
expressed in c4 compared to WT tumours. Thus we
needed to look further for an explanation of the similar
levels of glucose uptake by the two tumour types. One
possibility would be that the catalytic activity of a key
enzyme had been upregulated by a covalent post-trans-
lational modification. Three plausible candidate enzymes
that have been shown to play roles in the regulation of
glycolysis in various cancer tissues would be PK, PFK-1
and LDH [23-25]. We measured the activities of these
enzymes in homogenates of cultured WT and c4 cells
and tumours under optimal conditions (Table 2), and
found that the PK activity was significantly lower in the
c4 cells (p < 0.001) and tumours (p < 0.05) compared to
WT but that the activities of LDH and PFK were not
significantly different in either cells or tumours (>0.1).
PKM2, the embryonic form of pyruvate, might also play
a role [23]. In summary the activity of PK was signifi-
cantly lower in c4 cells and tumours, and the activities
of LDH and PFK-1 were not significantly different
between c4 and WT in either cells or tumours.
Allosteric activation of glycolysis
The results described so far concern studies performed
on the transcription, post-transcriptional modification
and catalytic activities (when assayed under optimal
conditions) of the glycolytic enzymes. They provide no
support for our original hypothesis that the surprisingly
rapid flux through the glycolytic pathway in c4 tumours
could have been due to a growth factor other than HIF-
1 upregulating transcription or inducing a covalent
post-translational modification of one or more glycolytic
enzymes. One final possibility remained: perhaps the c4
cells were upregulating their glycolytic pathway by a
classical allosteric mechanism, i.e. a metabolite from
another pathway activating (or releasing the inhibition
of) a glycolytic enzyme. Short-term control of glycoly-
sis has, for many years, been thought to occur princi-
pally by allosteric modulation of PFK-1 activity [26].
Among the allosteric modulators of PFK-1 is the inhi-
bitor ATP, a nucleotide that we had previously found
to be low in concentration in c4 tumours [9]; this sug-
gested a possible mechanism that would enhance
Table 1 Differentially expressed glycolytic and related proteins in Hepa-1 c4 and WT tumours
Spot number Protein Name c4/WT Ratio P values
47 Triose-phosphate isomerase (EC 5.3.1.1). -1.46 0.0005
42 Glyceraldehyde-3-phosphatedehydrogenase -1.35 0.0530
(EC1.2.1.12).
52 Phosphoglycerate kinase (EC 2.7.2.3). -1.89 0.0005
41 Phosphoglycerate mutase (EC 5.4.2.1). -1.44 0.0005
49 Fructose bisphosphate Aldolase A (EC 4.1.2.13). -2.05 0.0005
57 Enolase (EC 4.2.1.11). -1.35 0.0005
60 Pyruvate kinase (EC 2.7.1.40). -1.69 0.0005
59 D-3-phosphoglycerate dehydrogenase (EC 1.1.1.95). -2.39 0.0005
73 L-Lactate dehydrogenase A (EC 1.1.1.27). -1.25 0.0140
Differences in 2D gels between the Hepa-1 c4 and WT tumours.
The c4/WT ratios of proteins are selected as differences in 2D gels between the Hepa-1 c4 (n = 3) and WT (n = 3) tumours, each one with a technical replicate
using reciprocal labeling. The software produces ‘fold’ differences and P-values (t-test). The negative ratios indicate less in the Hepa-1 c4 than WT. See Additional
File for list (Table S1) of all the protein changes.
Table 2 Enzyme activity in Hepa-1c4 and WT cells and tumours
nmol/min/mg protein c4 cells c4 tumour WT cells WT tumour P value
LDH 1640 ± 511 861 ± 198 2373 ± 421 1269 ± 133 >0.1
PK 326 ± 4 177 ± 40 470 ± 15 292 ± 12 <0.05*
PFK 19.1 ± 2.0 15.5 ± 1.5 20.0 ± 1.5 17.8 ± 1.4 >0.1
The activities are expressed as mean ± sem (n = 3) for cultured cells and tumours. The assays were performed under optimal conditions (for details see
Methods).* denotes difference between c4 and WT.
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glycolysis in c4 tumours: reducing the allosteric inhibi-
tion of PFK-1. Furthermore, if the low ATP concentra-
tion were due to a change in the ATP:ADP ratio (as
distinct from a decrease in the total adenylate pool,
with the ATP:ADP ratio remaining constant) then the
equilibrium maintained by the enzyme adenylate kinase
would tend to raise the concentration of AMP - a
potent activator of PFK-1. Thus if c4 tumours have a
low concentration of ATP, a PFK-1 inhibitor, they
would be likely to have a high concentration of the
PFK-1 activator AMP; both of these abnormalities
would tend to activate PFK-1, thus enhancing glycoly-
tic flux. In order to test that hypothesis it was first
necessary to measure the tumour concentrations of
ATP, ADP and AMP.
Effects of HIF-1b deficiency on the adenine nucleotide
content
Measurements of adenine nucleotides (Table 3) in the
c4 and WT tumour types showed, as had been found
previously [9], that the ATP concentration in the c4
tumours was significantly lower (p < 0.03). In addition,
as we had predicted, the AMP content of the c4
tumours was significantly higher (p < 0.02) than in the
WT tumours, leading to an AMP/ATP ratio 4.5 fold
higher in the deficient c4 tumours. There was no signifi-
cant difference in the total adenine nucleotide content
between c4 and WT tumours.
Activity of PFK-1 at physiological adenine nucleotide
concentrations
Assay of PFK-1 (obtained by homogenizing WT and c4
cells) in the presence of optimal adenine nucleotide con-
centrations [13] had shown no significant difference
between WT and c4 cells (Table 2). However, when cel-
lular PFK-1 activity of the two homogenates made from
either cells or tumours was measured in the presence of
the adenine nucleotide concentrations that prevailed in
vivo in the respective cell types (AMP/ATP ratio of 0.40
for c4 and 0.09 for WT- see Table 3), the PFK-1 activity
was two-fold higher (p < 0.001) in the c4 cell homoge-
nate compared to WT and 1.6 fold higher in the tumour
homogenates (Figure 4).
Activation state of AMP Kinase
Since the AMP:ATP ratio was higher in the c4 tumours,
we hypothesised that they would have a higher level of
phospho-AMPKinase. Western blotting verified this -
see Figure 3 E.
Discussion
The HIF-1 pathway, which among other things promotes
growth and angiogenesis, is also considered essential for
the Warburg effect [7] and is activated in many cancers.
Inhibitors of both HIF-1 itself and many of its targets are
under development as anticancer agents. Thus there is
considerable interest in understanding how cancer cells
may be able to circumvent HIF-1 dysfunction. This study
focussed on the Hepa-1 c4 mouse tumour, a well-known
model in which HIF-1 activation does not take place
because of absence of a functional HIF-1b protein. Solid
tumours in animals, despite their obvious heterogeneities
of oxygenation and other metabolic parameters, are in
many respects better models for tumours in patients
(which also, of course, have all of these features) than are
cultured cells. Among other issues the artificial excess of
nutrients in cell culture complicates interpretation of
metabolic studies.
Previous studies have shown notably slower growth in
the HIF-1b deficient c4 tumours compared to the WT
Table 3 Measurement of adenine nucleotides in Hepa-1
c4 and WT tumours
μmol/g/wet wt c4 WT P value
ATP 0.72 ± 0.05 1.03 ± 0.1 <0.03*
ADP 0.57 ± 0.04 0.42 ± 0.04 <0.02*
AMP 0.28 ± 0.05 0.09 ± 0.02 <0.02*
Total AdN 2.07 ± 0.03 2.11 ± 0.08 >0.6
AMP:ATP 0.41 ± 0.11 0.09 ± 0.03 <0.01*
* denotes difference between c4 and WT.
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Figure 4 PFK activity measured in c4 and WT cells and
tumours under optimal conditions and those prevailing in vivo.
PFK activity (nmol/mg protein/min) measured either under optimal
conditions (1 mM ATP, 2 mM AMP) or under the conditions
prevailing in vivo (0.7 mM ATP and 0.25 mM AMP for c4; 1 mM ATP
and 0.04 mM AMP for WT). No significant difference in PFK activity
was seen when measured under optimal conditions comparing WT
and c4 tumours or cells (p > 0.1). However, under conditions
prevailing in vivo, PFK activity was significantly higher in c4 than in
WT cells or tumours (p < 0.005).
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tumours [3,4,9]. The present study confirmed this,
although between 24-28 days the growth rates of the c4
tumours and the WT tumours were not significantly dif-
ferent (P > 0.1). Thus it is clear that HIF-1b deficiency
impairs the initial growth of the c4 tumours. Glucose
uptake, measured in vivo by two different non-invasive
methods, was not significantly different in the c4 and
WT tumours. The PET study detected uptake and reten-
tion of the 18F moiety of 18 F-fluorodeoxyglucose
(18FDG), mainly in 18FDG itself and 18FDG-6P (since
FDG-6P, once formed, is not metabolised further at any
significant rate), so the readout is essentially 18FDG +
18FDG-6P. Our 19F MRS method which monitors the
uptake of 100% naturally abundant, non-radioactive FDG
also detects a combined peak of FDG and FDG-6P, so
the primary readout of the two methods shown in Fig-
ures 1B and 1C are identical. Although tracer uptake will
be affected by spatial heterogeneity of vascularity (and
although HIF-1 deficiency might be expected to decrease
vascularity), in a previous study [9] we found no differ-
ences in gross vascularity, or in the geometric pattern of
vascularity, or in the vascular density between the Hepa-
1 WT and c4 types. Similarly, a study of deoxygenated
haemoglobin distribution by BOLD-MRI found no differ-
ence between the two tumour types [9].
These results on glucose uptake were in keeping with
our previous results in cultured cells [10] where no dif-
ference was found in the output of lactate (an indicator
of glycolytic flux) between c4 and WT cells cultured
under normoxia or hypoxia for 18 hours [10], and also
in a previous study on c4 and WT tumours where simi-
lar levels of lactate were noted [9]. The normal increase
in glycolysis when the c4 cells were incubated at low
pO2 was particularly surprising, as it implied that
despite having deficient HIF-1b and being unable to
form the HIF-1 complex in their nuclei, c4 cells were
nevertheless able to respond to hypoxia. Since our origi-
nal publication on c4 and WT tumours in mice [9], we
have confirmed by Western blotting that no HIF-1a or
HIF-1b was detectable in the cell nuclei [see [10]] of
cultured c4 cells. Failure to find HIF-1b in the cell
nucleus also rules out HIF pathways involving HIF-2a
or HIF-3a, since both are thought to act in the nucleus
as complexes with HIF-1b. We have also previously
shown [10] that the HIF-1-associated Hypoxia Response
Elements (HREs) for phosphoglycerate kinase and lac-
tate dehydrogenase were not activated in the c4 cells, a
result in keeping with the downregulation of expression
of these and other glycolytic enzymes found in the pre-
sent study (Tables 1 and 2).
Since Akt [18,27] and c-Myc [19,20] have been pro-
posed to upregulate glucose metabolism and glycolysis
and to be responsible for the Warburg effect indepen-
dently of HIF-1, measurements of these factors were
made to see if they could contribute to the high uptake
of glucose in the WT and c4 tumours. Phospho-Akt was
expressed at a lower level in the c4 than the WT
tumours and could therefore not account for their high
glucose uptake. However, there was no difference in the
c-Myc expression between the WT and c4 tumours, so
it was possible, in principle, that c-Myc was driving
both tumour growth and glucose uptake to the same
extent in the HIF-1b deficient c4 tumours as in the WT
tumours. Another consideration was that c-Myc activity
is antagonised by HIF-1 [28], so the normal level of c-
Myc expression in c4 tumours might have its action
boosted by decreased HIF-1 antagonism.
However, none of the possibilities mentioned in the pre-
vious paragraph was relevant, since we found in proteomic
studies by DIGE (which can reliably quantify differences as
low as 10% in expression of enzymes and their post-trans-
lationally modified products) that glycolytic enzymes were
present at significantly lower concentrations in the HIF-1b
deficient c4 tumours than in the WT tumours (Table 1).
The effect of c-Myc is to increase expression of the glyco-
lytic enzymes but we found decreased expression of most
of the glycolytic enzymes in c4 tumours. Those findings
would therefore argue against a role for c-Myc, or any
other factor that activates transcription, in upregulating
the glycolytic pathway of c4 tumours. Furthermore, c-Myc
tends to enhance tumour growth rate, whereas the growth
rate of c4 tumours was slower than that of WT tumours.
It has been shown previously that mouse cell lines
lacking HIF-1 fail to activate PDK1 [21,22]. Consistent
with that possibility, our studies showed lower PDK-1
(and PDK-2) expression in c4 tumours compared with
WT. Dang and colleagues [22] found that retrovirally-
forced expression of PDK1 prevents apoptosis and aug-
ments ATP production. Our c4 tumours had lower
expression of PDK1, lower ATP and slower growth rate
compared to WT tumours; all of these observations
would be consistent with the results of Dang [22].
It was also recently shown [29] that replacement of
PKM2 by normal PKM1 abolished the Warburg effect
(aerobic glycolysis) in cancer cells, so overexpression of
PKM2 in c4 cells might have accounted for their ele-
vated glycolysis. However c4 tumours showed lower
PKM2 protein content and lower PK activity than WT
tumours, so PKM2 could not have been responsible for
the upregulation of their glycolytic flux.
Immunohistochemical staining showed a lower expres-
sion of the glucose transporters GLUT 1 in c4 com-
pared to WT tumours, as had been found previously
[3,4]. However, GLUT-2 (the specific liver glucose trans-
porter) stained equally well in c4 and WT tumours.
Since both c4 and WT tumours originally arose from
liver cells it is perhaps not surprising that they express
the liver-specific glucose transporter. However, the
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degree of staining was no higher in the c4 than in the
WT tumours, so elevated glucose transporter expression
could not be compensating for the decreased expression
of glycolytic enzymes in HIF-1b deficient c4 tumours.
Previous reports of low ATP levels in c4 cells or tumours
[9], and in HIF-1a deficient transformed astrocytes [30],
suggest that loss of either HIF-1a or b leads to a lower
tumour energy state. However, no previous studies have
investigated whether the low ATP is associated with a gen-
eral decrease in the adenine nucleotide pool (i.e. in the sum
of ATP, ADP and AMP) or alternatively a shift in the equi-
librium between ATP, ADP and AMP, with the total ade-
nine nucleotide pool (ATP + ADP + AMP) remaining
constant. In previous studies on the concentration of ATP
in WT and c4 tumours [9], both by an enzymatic assay and
by single photon imaging and bioluminescence, we had
found ATP levels so low (20% of those in WT tumours)
that we had discounted the possibility that they could be
due to a shift in the equilibrium between ATP, ADP and
AMP, and assumed that they must have been due to a
decrease in the total adenylate pool. The similar 31P MRS
spectra of the two tumour types gave qualitative support to
that interpretation. In the present study, however, we used
HPLC to make precise measurements all the adenine
nucleotide concentrations in WT and c4 tumours, and
these results led us to a different conclusion.
The results in Table 3 show that in c4 tumours the
fall in ATP is primarily due to a shift in the ATP:ADP
equilibrium rather than a fall in the total adenylate pool:
ATP/ADP is 1.4, compared with 2.4 in WT tumours,
whereas total adenine nucleotides were almost identical
(p > 0.1). Furthermore, AMP was more than 3-fold
higher in c4 than WT tumours (p < 0.01), and the c4
tumour AMP/ATP ratio was 4.5 fold higher. In our ear-
lier assays the ATP content of c4 tumours was found to
be ~20% of that in WT tumours [9], the present results
(i.e. that ATP in c4 tumours was ~70% of that in WT
tumours) may understate the abnormality. AMP is
extensively bound to tissue proteins [31], and since
some high-affinity binding sites are likely to become
saturated, the three-fold higher total AMP content of c4
tumours might correspond to an even greater difference
in free cytosolic AMP. Taken together, these considera-
tions suggest that the lower ATP concentration would
reduce allosteric inhibition, and the very much increased
free AMP concentration in c4 tumours might lead to a
substantial allosteric activation of PFK-1.
The main regulatory enzyme of the glycolytic pathway,
PFK-1, is inhibited allosterically by cytosolic concentra-
tions of ATP, and activated by AMP [26]. The low [ATP]
and high [AMP] in c4 tumours therefore suggest an expla-
nation for their paradoxically normal glycolysis despite
lower expression of glycolytic enzymes. The PFK-1 activity
studies in Figure 4 show that PFK-1 activity would be two-
fold higher at the prevailing ATP/AMP ratio in c4 cells
than at the one in WT cells. This confirms the hypothesis
that glycolytic flux in WT cells is “throttled back” by ATP
inhibition at the PFK-1 step, and that c4 tumours maintain
a normal rate of glycolysis by running at a lower inhibitory
[ATP] and a much higher activating [AMP]. The report
that HIF-1a deficient transformed astrocytes also have low
ATP levels and normal rates of lactate formation [30] sug-
gests that they too may use this mechanism to maintain
their glycolytic flux despite probable downregulation of
HIF-1 induced glycolytic enzyme expression.
Metabolic control analysis of the glycolytic pathway
suggests that control by ATP levels will be more
important than control via changes in the expression
of PFK-1 [32], and in several studies [reviewed in [33]]
forced over-expression of PFK-1 has not led to faster
glycolytic flux. The hypothesis we have outlined in the
preceding paragraph is compatible with both of these
observations. In our hypothesis the main driver of gly-
colytic flux would be demand for ATP (for tumour cell
growth), so ATP control of glycolysis would indeed be
paramount, as predicted by metabolic control analysis.
Secondly, the normal cells and yeasts in which PFK-1
overexpression studies have been performed started
with normal levels of PFK-1; thus additional expression
of PFK-1 would have been surplus to requirements and
would probably be inhibited (like the endogenous PFK-
1) by the normal level of ATP present. The c4 tumour
cells, in contrast, are deficient in most glycolytic
enzymes, but they are driven by oncogene expression
to rapid growth, which is primarily fuelled by glucose
metabolism. Metabolic control analysis, indeed, sug-
gests that it is just such a coordinated downregulation
of expression of many enzymes in a pathway that is
necessary for reducing pathway flux. In these excep-
tional circumstances of a glycolytic pathway downregu-
lated by underexpression of many of its enzymes,
upregulation of PFK-1 activity is a plausible mechan-
ism (Figure 5) for increasing glycolytic flux [34].
The high AMP and low ATP in c4 cells are also likely
to have another significant consequence: they will tend
to activate AMP-activated protein kinase (AMP-K), an
important metabolic control enzyme that coordinates
cellular proliferation with carbon source availability [35].
AMP-K activation is enhanced both by low ATP con-
centrations and by high AMP concentrations [36]. Our
adenine nucleotide results suggest that AMP-K would
be more active in c4 tumours, and this was demon-
strated by immunoblotting (Figure 3E), which would
tend to down-regulate cellular proliferation; that effect
could account for the lower growth rate of c4 tumours
(Figure 1).
Recent evidence [37] showing that Ras may induce 6-
phosphofructo-2-kinase/fructose-2,6-bisphosphatase,
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also a transcriptional target of HIF-1 [24], suggests that
fructose-2,6-bisphosphate (F26BP), another allosteric
activator of PFK, may also play a role. However since
this mechanism requires a functioning HIF-1 pathway,
we considered it unlikely in the c4 HIF-1b deficient
tumours.
HIF-1 is currently a target for anticancer drug devel-
opment [5,6], with the aim of inhibiting tumour growth.
However, the present results with the c4 tumour, which
is completely unable to upregulate HIF-1, and thus
could act as a model for a completely effective anti-HIF-
1 drug, shows that the anti-proliferative action of even
complete HIF inhibition is quite modest, and escape
from inhibition begins after a few weeks (Figure 1). In
addition, a plausible surrogate biomarker for monitoring
the anti-proliferative action of anti-HIF-1 drugs would
appear to be 18FDG-PET: since HIF-1 upregulates glyco-
lysis an anti-HIF-1 drug might be expected to inhibit
tumour uptake of the glucose analogue 18FDG. For
instance, inhibitors of mTOR (some of which are
already approved for cancer treatment) decrease the
level of HIF-1a, and it has been suggested that their
efficacy might be assessed by their ability to reverse
tumour-associated 18FDG uptake [7]. Unfortunately the
results reported in this study show that c4 tumours, in
which HIF-1 (and also HIF-2 and HIF-3) are completely
inactive, take up glucose analogues at the same rate as
WT tumours. Thus 18FDG-PET may not be a good way
to assess the presumed anti-proliferative action of an
anti-HIF-1 drug.
Conclusions
The present study shows that despite the absence of
active HIF-1 and therefore reduced amounts of most
enzymes in the glycolytic pathway, c4 tumours perform
glycolysis at the normal rate. The mechanism that
allows a normal rate of glycolysis seems to be allosteric
up-regulation of PFK-1. These results show that the
metabolic adaptations to HIF-1 effects are complex, and
can involve activation of AMP Kinase.
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Figure 5 Pathways concerned with the regulation of glycolysis and the effects of HIF-1 deficiency in Hepa-1 tumours. In the wild-type
tumours (WT), [ATP] would tend to inhibit PFK activity. However in HIF-1 deficiency (c4), enzymes in the glycolytic pathway are down-regulated
to 42-74% of the WT protein expression and the resulting decrease in [ATP] causes an increase in [AMP] (due to the adenylate kinase
equilibrium). AMP acts as an allosteric activator of PFK, and the ATP/AMP ratio in c4 tumours doubles the PFK catalytic activity (see Figure 4),
allowing glycolytic flux through the pathway (glucose to lactate) to be maintained at WT levels.
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Since HIF-1 inhibitors would be expected to downre-
gulate expression of glycolytic enzymes and thus inhibit
flux through the glycolytic pathway, the obvious way to
test the action of such drugs on tumours would be to
look for suppression of 18FDG uptake using PET. The
results in the present paper suggest that this would not
be an effective strategy. In c4 tumours, even in the com-
plete absence of a functioning HIF pathway which led to
a general downregulation of expression of the glycolytic
pathway, there was a normal glycolytic flux compared to
WT cells and normal FDG uptake compared to WT
tumours. It seems that these tumour cells have sufficient
reserve glycolytic capacity, and that it can be called into
action by allosteric upregulation of PFK-1 activity.
Additional material
Additional File 1: Methods used for Proteomic Analysis Figure S1.
showing 2-D gel comparing protein profiles of Hepa-1 c4 (deficient in
HIF-1b) and WT tumours using the DIGE approach. Table S1. shows
differences in protein profiles between Hepa-1 c4 (deficient in HIF-1b)
and WT tumours (complete list). Further details of 18FDG PET method.
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